 |
|
|
|
|
|
|
 |
There are several factors that may increase a man’s chances of getting prostate cancer, some of which may include:
- Race. Medical experts don't know why race plays a role in the development of prostate cancer, but they do know it is less common among Caucasian men than among African Americans. African Americans are also twice as likely to die of the cancer, and the condition occurs more often in Caucasian than in Asian men.
- Nationality. The cancer is more commonly found in North America and northwestern Europe and is less common in Africa, Asia, Central and South America.
- Family History. Patients with either a brother or father who had prostate cancer are more likely to get the disease. This is especially true if the relatives were young when they developed prostate cancer. A small 5%-10% of prostate cancers are linked to changes in a man's DNA, which is inherited from our patents. DNA comprises our genes, which control how cells behave.
- Age. The older a man gets, the more likely he will develop prostate cancer.
|
|
|
|
|
|
Indications and Usage
TRELSTAR® Depot and TRELSTAR®
LA are indicated in the palliative treatment of advanced prostate cancer. TRELSTAR
Depot or TRELSTAR LA offer an alternative treatment for prostate cancer when orchiectomy
or estrogen administration are either not indicated or unacceptable to the patient. |
|
|
|
Safety Information
|
|
The most commonly reported adverse events associated with the use of TRELSTAR®
Depot/TRELSTAR® LA included hot flushes (58.6%/73.0%), skeletal pain
(12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%),
and edema in legs (0.0%/6.3%) . TRELSTAR is contraindicated in women who are or
may become pregnant as well as patients who are hypersensitive to triptorelin, other
LHRH agonists, or LHRH . Infrequent postmarketing reports of anaphylactic shock
and angioedema have been received since 1986 (global experience) . As with all LHRH
agonists, triptorelin causes an initial transient increase in testosterone levels.
Patients may experience the onset or exacerbation of symptoms during this period,
including bone pain, neuropathy, hematuria, spinal cord compression, or urethral
or bladder outlet obstruction. Patients with metastatic vertebral lesions and/or
urinary tract obstruction should be closely observed. |
|
|
|
|
|
|
|
|
|
